Dear Sir, Please find the attachment. Regards, For MRC Agrotech Limited Compliance Officer/ Authorised Signatory
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MRC Agrotech has revised the use of proceeds from its preferential issue, providing a detailed breakdown after the BSE asked for clearer bifurcation. Total issue size is Rs. 428.59 lakhs, which will now go entirely into growth activities since all outstanding borrowings were already repaid from internal accruals before June 2025. The largest chunk of Rs. 313.30 lakhs is earmarked for working capital (raw materials, trade creditors, distributor advances, employee dues) between January-March 2026. Another Rs. 100 lakhs is set aside for future funding, including Rs. 25 lakhs for integrating the MARSAPI Lifesciences acquisition, Rs. 30 lakhs for a new R&D facility at Belapur, Rs. 20 lakhs for launching two new bio-formulation products, and Rs. 25 lakhs for early-stage expansion into nutraceuticals and soil-health products. The remaining Rs. 15.29 lakhs will go to general corporate purposes such as listing fees, legal expenses, and ERP upgrades.
For shareholders, this signals that the company has cleaned up its debt on its own and is now deploying fresh capital purely into operational and growth needs — working capital, an R&D lab, product launches, and the MARSAPI acquisition integration. The shift away from debt repayment toward expansion could support future revenue growth but also means there is no immediate deleveraging benefit from these proceeds.